Conjugated equine estrogens + medroxyprogesterone acetate
Intervention1 paper3 findings
- Human trial1
Outcomes
2Mortality
no changein humans1HR 1.18Moderate certainty
1 study
Mortality
no changein humans1HR 1.18Moderate certainty
Conjugated equine estrogens + medroxyprogesterone acetate has no effect on mortality in humans (HR 1.18; 95% CI, 0.67-2.07).
Human trial0.625 mg/d + 2.5 mg/dnearly 24 yearsfemalesn = 16,608
Menopausal hormone therapy and primary liver cancer: long-term follow-up of the women's health initiative randomized trials · British journal of cancer · 16 Sep 2026
Liver cancer
no changein humans1HR 1.63Moderate certainty
1 study
Liver cancer
no changein humans1HR 1.63Moderate certainty
Conjugated equine estrogens + medroxyprogesterone acetate has no effect on liver cancer in humans (HR 1.63; 95% CI, 0.91-2.92).
Human trial0.625 mg/d + 2.5 mg/dnearly 24 yearsfemalesn = 16,608
Menopausal hormone therapy and primary liver cancer: long-term follow-up of the women's health initiative randomized trials · British journal of cancer · 16 Sep 2026
Associations
1Liver cancer
upin humans1HR 4.3High certainty
1 study
Liver cancer
upin humans1HR 4.3High certainty
Conjugated equine estrogens + medroxyprogesterone acetate raises the risk of liver cancer in humans (HR 4.30, 95% CI, 1.46-12.72).
Human trialprior oral contraceptive users0.625 mg/d + 2.5 mg/dnearly 24 yearsfemales
Menopausal hormone therapy and primary liver cancer: long-term follow-up of the women's health initiative randomized trials · British journal of cancer · 16 Sep 2026